Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea B Apolo

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
European Urology Oncology|June 20, 2021
Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder CancerGianluca Giannarini, Neeraj Agarwal, Andrea B Apolo, et al.
JAMA Dermatology|November 27, 2014
Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinibRena C Zuo, Andrea B Apolo, John J DiGiovanna, et al.
Cancer|December 1, 2015
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agentsChristopher M Tully, Andrea B Apolo, Emily C Zabor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2019
Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder CancerVid Leko, Lucas A McDuffie, Zhili Zheng, et al.
Journal of Digital Imaging|January 12, 2017
ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer DatabasesNikhil Goyal, Andrea B Apolo, Eliana D Berman, et al.
Journal of the National Cancer Institute|February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapyAndrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Journal for Immunotherapy of Cancer|November 21, 2020
Efficacy and immune-related adverse event associations in avelumab-treated patientsKaren Kelly, Juliane Manitz, Manish R Patel, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
BJU International|March 6, 2025
Understanding patient perspectives in the management of their muscle-invasive bladder cancerDeepro Chowdhury, Andrea B Apolo, Di Maria Jiang, et al.
The Oncologist|July 24, 2014
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinomaNeeraj Agarwal, Andrea B Apolo, Che-Kai Tsao, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
European Urology Oncology|June 20, 2021
Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder CancerGianluca Giannarini, Neeraj Agarwal, Andrea B Apolo, et al.
JAMA Dermatology|November 27, 2014
Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinibRena C Zuo, Andrea B Apolo, John J DiGiovanna, et al.
Cancer|December 1, 2015
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agentsChristopher M Tully, Andrea B Apolo, Emily C Zabor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2019
Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder CancerVid Leko, Lucas A McDuffie, Zhili Zheng, et al.
Journal of Digital Imaging|January 12, 2017
ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer DatabasesNikhil Goyal, Andrea B Apolo, Eliana D Berman, et al.
Journal of the National Cancer Institute|February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapyAndrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Journal for Immunotherapy of Cancer|November 21, 2020
Efficacy and immune-related adverse event associations in avelumab-treated patientsKaren Kelly, Juliane Manitz, Manish R Patel, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
BJU International|March 6, 2025
Understanding patient perspectives in the management of their muscle-invasive bladder cancerDeepro Chowdhury, Andrea B Apolo, Di Maria Jiang, et al.
The Oncologist|July 24, 2014
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinomaNeeraj Agarwal, Andrea B Apolo, Che-Kai Tsao, et al.
Pageof 12